09 March, 2022

Sky Technologies Provides Fourth Quarter and Fiscal Year 2021 Corporate Update

 

Closes Successful $23.1 Million IPO and Commences Trading on the Nasdaq

 MIAMI, FL / ACCESSWIRE / Knowledge Bylanes / March 8, 2022 /SQL Technologies Corp. (NASDAQ:SKYX) ("Sky Technologies" or "the Company"), a Company significantly enhancing safety in homes and buildings as well as smart home lifestyle, with highly disruptive smart platform technologies and over 60 issued and pending patents globally, today reported its financial results for the fourth quarter ended December 31, 2021.

Fourth Quarter 2021 and Subsequent Operational Highlights:

 On February 10, 2022, successfully completed its upsized $23.1 million initial public offering (IPO) on the Nasdaq Capital Market, selling 1,650,000 shares of common stock to the public at $14 per share.
 Announced the upcoming launch of the new universal SkyPlug, the SkyHome App and the smart connected SkyPlug, as well as an accompanying line of GE-branded smart ceiling fans and lighting fixtures, in the first half of 2022.
 Positioning for the public launch of Sky Platform, the Company’s all-in-one smart home solution, in the second half of 2022.
 As of December 31, 2021, the Company’s cash and cash equivalents were approximately $10.4 million, which excludes net proceeds from its February 2022 IPO.

The full text of the Company’s 2021 Annual Report on Form 10-K was filed with the SEC on March 8, 2022 and can be found here.

Management Commentary

“The fourth quarter of 2021 represented a transformational period for Sky Technologies, building the foundation for our transition to a public company – further accelerated by the infusion of new capital from our IPO to expedite our commercialization pathway,” said Rani Kohen, Executive Chairman of Sky Technologies. “We believe our Nasdaq listing will help elevate the Company’s public profile, expand our shareholder base, improve liquidity and enhance shareholder value. The net proceeds to Sky Technologies from the offering amounted to $20 million.

“Launch of our next-generation SkyPlug and Sky Platform product lines are moving ahead, and we anticipate coming to market with both products this year. The SkyPlug enables consumers to install plug-and-play smart home fixtures into a receptacle quickly and safely without the need for a professional installer, and the Sky Platform is an all-in-one smart home solution, integrating several smart home & safety features such as a motion sensor, security camera and Wi-Fi extender. We believe our breakthrough platform technology has the ability to become the standard for smart home and office fixtures, with countless applications and potential addressable installations in the billions globally.

“Moving into 2022 we expect to launch our new universal SkyPlug, our SkyHome App, and our smart SkyPlug, as well as an accompanying line of smart ceiling fans and lighting fixtures leveraging GE-branding through our branding and licensing partnership with General Electric, in the first half of 2022. This will be followed by the launch of our widely anticipated, all-in-one Sky Platform in the second half of 2022. In anticipation, we are ramping our go-to-market strategy to include public relations and marketing campaigns that emphasize education of our products and how they can be used to create safer and smarter homes. We expect to provide additional announcements on our product launch timeline in the coming months – helping to create sustainable, long-term value for our shareholders.”

FY 2021 Financial Results

Selling, general and administrative expenses in 2021 were $5.1 million, as compared to $8.7 million for the prior year.

Net loss in 2021 decreased to $5.9 million, as compared to a net loss of $9.4 million for the prior year.

Cash and cash equivalents totaled $10.4 million as of December 31, 2021, excluding net proceeds from its IPO completed in February 2022.

There will be no earnings call related to the Company’s 2021 annual report.

About SQL Technologies Corp.

As electricity is a standard in every home and building, our mission is to make homes and buildings become safe-advanced and smart as the standard.

SQL Technologies Corp. (NASDAQ: SKYX) d/b/a Sky Technologies has a series of highly disruptive advanced-safe-smart platform technologies, with over 60 U.S. and global patents and patent pending applications. Our technologies place an emphasis on high quality and ease of use, while significantly enhancing both safety and lifestyle in homes and buildings. We believe that our products are a necessity in every room in both homes and other buildings in the U.S. and globally. For more information, please visit our website at https://skyplug.com or follow us on LinkedIn

Cautionary Statement Concerning Forward-Looking Statements

 This press release contains forward-looking statements that are based on management’s beliefs and assumptions and on information currently available to management. All statements other than statements of historical facts contained in this press release, including statements regarding the Company’s strategy, future financial condition, future operations, projected costs, prospects, plans, objectives of management, outlook, and expected market growth, are forward-looking statements. In some cases, you can identify forward-looking statements by the following words: “may,” “might,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “aim,” “objective,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing,” “target,” “seek” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors, many of which have been, and may further be, exacerbated by the COVID-19 pandemic, that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements.

Forward-looking statements in this press release include, but are not limited to, statements about: the Company’s ability to successfully launch, develop additional features and achieve market acceptance of its smart products and technologies, access and integrate its products and technologies with third-party platforms or technologies, respond to rapidly changing technology and customer demands, and compete in its industry; the Company’s financial performance and liquidity, including the Company’s ability to successfully generate sufficient revenue to support its operations; the Company’s ability to expand, operate and successfully manage its operations, including managing its business transformation in connection with evolving its business strategy to focus on smart products and technologies; the Company’s ability to raise additional financing to support its operations as needed; the Company’s ability to comply with the terms of, and timely repay, its current debt financing; the impact of the COVID-19 pandemic on the Company’s business and operations; the Company’s reliance on a limited number of third-party manufacturers and suppliers and its ability to successfully reduce its production costs; the Company’s potential dependence upon a limited number of customers and/or on contracts awarded through competitive bidding processes; any downturn in the cyclical industries in which the Company’s customers operate; the Company’s ability to acquire other businesses, license rights, form alliances or dispose of operations when desired; the Company’s ability to comply with regulations relating to applicable quality standards; the Company’s ability to maintain its license agreement with General Electric (GE); the Company’s ability to maintain, protect and enhance its intellectual property; the potential outcome of any legal proceedings; the Company’s ability to successfully sell and distribute its products and technologies; the Company’s ability to retain key executives and qualified personnel; the Company’s ability to successfully manage its planned development and expansion, including the additional costs of being a public company; the Company’s ability to maintain effective internal control over financial reporting and disclosure controls and procedures; the potential impact of unstable market and economic conditions on the Company’s business, financial condition and stock price; the potential impact of cybersecurity breaches or disruptions to the Company’s information systems, including its cloud-based infrastructure; the potential impact of natural disasters and other catastrophic events, such as the COVID-19 pandemic; risks related to ownership of the Company’s common stock; and the potential impact of anti-takeover and director and officer liability provisions in the Company’s charter documents and under Florida law. Other important factors that may cause actual results to differ materially from those expressed in the forward-looking statements are discussed in the Company’s filings with the Securities and Exchange Commission, including the section of the Annual Report on Form 10-K for its 2021 fiscal year titled “Risk Factors” and the “Risk Factors” section in its prospectus dated February 10, 2022. As a result of these factors, the Company cannot assure you that its forward-looking statements will prove to be accurate. Furthermore, if the forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by the Company or any other person that the Company will achieve its objectives and plans in any specified time frame, or at all.

The forward-looking statements in this press release represent the Company’s views as of the date of this press release. The Company anticipates that subsequent events and developments will cause its views to change; however, the Company undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by U.S. federal securities laws. You should, therefore, not rely on these forward-looking statements as representing the Company’s views as of any date subsequent to the date of this press release.

Investor Relations Contact:

Lucas A. Zimmerman

MZ North America

(949) 259-4987

SKYX@mzgroup.us

 

SQL Technologies Corp. and Subsidiary

Unaudited Consolidated Balance Sheets

  December 31, 2021  December 31, 2020 
Assets      
Current assets:        
Cash and cash equivalents $10,426,249  $2,308,871 
Accounts receivable, net  115   1,543 
Inventory  918,651   918,651 
Prepaid expenses  40,903    
Total current assets  11,385,918   3,229,065 
         
Other assets:        
Furniture and equipment, net  25,710   67,735 
Patents, net  540,033   403,092 
Other assets  2,174   2,174 
Total other assets  567,917   473,001 
         
Total Assets $11,953,835  $3,702,066 
         
Liabilities and Stockholders’ Deficit        
         
Current liabilities:        
Accounts payable $507,250  $1,008,051 
Notes payable, current  404,648   344,032 
Accrued expenses  522,086   358,621 
        
GE royalty obligation  1,200,000   500,000 
Total current liabilities  2,633,984   2,210,704 
         
Long term liabilities:        
Notes payable  5,492,572   5,286,642 
Convertible notes  1,300,000   1,250,000 
GE royalty obligation  2,638,000   3,838,000 
Total long-term liabilities  9,430,572   10,374,642 
         
Total liabilities  12,064,556   12,585,346 
         
Commitments and Contingent Liabilities:        
Redeemable preferred stock – subject to redemption: $0 par value; 20,000,000 shares authorized; 13,256,936 and 13,456,936 shares issued and outstanding at December 31, 2021 and December 31, 2020  3,314,233   3,364,233 
         
Stockholders’ Deficit:        
Common stock: $0 par value, 500,000,000 shares authorized; 66,295,288 and 64,515,231 shares issued and outstanding at December 31, 2021 and December 31, 2020, respectively  57,356,139   34,353,592 
Common stock to be issued  -   8,088,474 
Additional paid-in capital  13,524,247   13,755,891 
Accumulated deficit  (74,296,898)  (68,410,028)
Total stockholders’ deficit  (3,314,512)  (12,212,071)
Non-controlling interest  (35,442)  (35,442)
Total deficit  (3,349,954)  (12,247,513)
         
Total Liabilities and Stockholders’ Deficit $11,953,835  $3,702,066 
 

SQL Technologies Corp. and Subsidiary

Unaudited Consolidated Statements of Operations

 

  For the Year Ended December 31, 
  2021  2020 
Revenue $43,109  $258,376 
Cost of revenues  (149,286)  (503,033)
Gross (loss)  (106,177)  (244,657)
Selling, general and administrative expenses  5,081,906   8,741,320 
Loss from operations  (5,188,083)  (8,985,977)
Other income / (expense)        
Interest expense  (560,418)  (515,515)
Other income, Loan forgiveness  10,000   257,468 
Gain on exchange  8,051   408 
Interest income  36   1,511 
Total other income (expense), net  (542,331)  (256,128)
         
Net loss including noncontrolling interest  (5,730,414)  (9,242,105)
        
Preferred dividends  129,456   130,206 
Net loss attributed to common shareholders $(5,859,870) $(9,372,311)
         
Net loss per share - basic and diluted $(0.09) $(0.15)
         
Weighted average number of common shares outstanding during the year – basic and diluted  64,943,703   62,754,177 
 

SQL Technologies Corp. and Subsidiary

Unaudited Consolidated Statements of Cash Flows

  For the Year Ended December 31, 
  2021  2020 
Cash flows from operating activities:        
Net loss attributable to SQL Technologies $(5,730,414) $(9,242,105)
Adjustments to reconcile net loss to net cash used in operating activities:        
Depreciation expense  42,025   74,277 
Amortization of patent  42,262   32,032 
(Other income), Loan forgiveness  (10,000)  (257,468)
Non-cash equity-based compensation expense  464,953   5,188,428 
Non-cash equity-based compensation expense, related party  998,080     
Change in operating assets and liabilities:        
Accounts receivable  1,428   417,994 
Prepaid expenses  (40,902)  5,629 
Inventory  -   325,357 
Right-to-use assets  -   54,112 
Other assets  -   16,080 
Royalty obligation  (500,000)  (87,508)
Lease, current      (53,210)
Accounts payable  (58,651)  158,468 
Accrued expenses  88,464   358,621 
Net cash used in operating activities  (4,627,755)  (3,129,293)
         
Cash flows from investing activities:        
Purchase of property and equipment  -   (15,336)
Payment of patent costs  (179,203)  (94,540)
Net cash used in investing activities  (179,203)  (109,876)
         
Cash flows from financing activities:        
Proceeds from common stock issuance  13,039,396   100,009 
Proceeds from exercise of warrants  -   2,025,000 
Proceeds from exercise of options  130,000   - 
Proceeds from - PPP1 notes payable  178,235   279,500 
Proceeds from - EIDL notes payable  -   150,000 
Proceeds from issuance of convertible notes  50,000   1,250,000 
Dividends paid  (129,456)  (130,206)
Principal repayments of – PPP1 note payable  (839)   
Principal repayments on note  (343,000)   
Net cash provided by financing activities  12,924,336   3,674,303 
         
Increase (Decrease) cash and cash equivalents  8,117,378   435,134 
Cash and cash equivalents at beginning of period  2,308,871   1,873,737 
Cash and cash equivalents at end of period $10,426,249  $2,308,871 
         
Supplementary disclosure of non-cash financing activities:        
Issuance of common stock listed as “to be issued” in prior year  8,088,474   - 
Reclassed of accrued interest to note  442,150   - 
Stock issuance, placement fees  502,040   - 
Preferred stock conversion to common  50,000   - 
Stock issuance, cashless exercise of warrants  74,375   - 
         
Cash paid during the year for:        
Interest $560,418  $515,515 
 

SOURCE:SQL Technologies, Inc. dba Sky Technologies

فندق دبليو دبي – النخلة يعيد تقديم فعالية "اشحن طاقتك" لنهاية أسبوع رائعة من اللياقة والمتعة

عزز لياقتك واشحن طاقتك لشعور ومظهر أفضل

 

A picture containing water, sky, outdoor, dayDescription automatically generated

 

دبي، مارس 2022: استعدوا لقضاء أجمل الأوقات والاسترخاء مع برنامج "اشحن طاقتك" المحبوب في فندق دبليو دبي – النخلة، والذي يعود إليكم ليجدد نظام اللياقة اليومي ويضفي عليه مزيدًا من الحيوية من خلال برامج التمرين والاسترخاء والمغامرات والعديد من حصص التمارين الخارجية مع أفضل المدربين، بالإضافة إلى وجبة "شوجار بالم ريبابليك" في الفندق لعيش أسلوب الحياة الأمثل لتعزيز الطاقة والتخلص من السموم.

 

وفي الفترة من 26 إلى 27 مارس 2022، يمكن لمحبي اللياقة الاستمتاع بتجربة استثنائية في نهاية أسبوع حافلة بالطاقة والحيوية مع جلسات التمرين بقيادة UFC Gym الشهير ببرامجه الفعالة للياقة والارتقاء بمستوى التمارين.

 

يبدأ اليوم بتمرين MMA Fitness & Conditioning على الشاطئ لمدة 45 دقيقة والمساعدة في تعزيز قوة الجسم وتحمله وتناسقه، تتبعها حصص التمرين اليومي Daily Ultimate Training  في حديقة سيكرت جاردن بالفندق، والتي تتضمن تمارين عالية الجهد تتركّز شدتها على فترات زمنية محددة. وتستمر التجربة المثيرة مع حصص اليوغا في شرفة FIT، والمثالية لتحسين المرونة وتعزيز قوة الجذع. 

 

ويمكن للضيوف بعدها الاسترخاء في WET Deck بجانب بركة السباحة والاستمتاع بأطباق بالم شوغار ريبابليك والمرطبات المنعشة على أجمل الأنغام والترفيه الحي.

 

ابدؤوا يومكم الثاني بحيوية ونشاط، حيث يبدأ برنامج اللياقة صباح الأحد بجلسة Killer Core في حديقة سيكرت جاردن، وتتضمن تمارين عالية الشدة لمنطقة البطن لمدة 30 دقيقة، ويتبعها تمرين  Legs & Glutes HIIT Workout  لنحت الجسم وتناسقه من الأسفل. وينتهي البرنامج التدريبي بجلسة Paddle Board لمدة 45 دقيقة، والتي تقام على إطلالة خلابة لجزيرة النخلة ومرسى دبي.

 

 تبدأ أسعار فعالية "اشحن طاقتك" من 300 درهم إماراتي للشخص الواحد وتشمل برنامج التمارين الكامل يومي السبت والأحد مع وجبة برانش بالم شوغار ريبابليك يوم السبت في WET Deck.

 

اشحن طاقتك

التاريخ:   26 – 27 مارس 2022

الفعالية:

  • اشحن طاقتك: تشمل كافة جلسات التمارين يومي السبت والأحد
  • "بالم شوغار ريبابليك" في WET Deck  لمدة أربع ساعات يوم السبت

السعر: 300 درهم إماراتي للشخص الواحد

للحجز: الأماكن محدودًا نظرًا لاتباع تدابير السلامة والتباعد الاجتماعي، فاحجزوا الآن لتحصلوا على مقاعدكم من خلال الاتصال على 800UFCGYM  أو socialmedia.wthepalm@whotels.com

 

برنامج الفعالية

 

السبت 26 مارس:

  • 9:00 صباحًا: حصة MMA Fitness & Conditioning على الشاطئ
  • 10:15 صباحًا: تمرين Daily Ultimate Training في حديقة سيكرت جاردن
  • 11:30 صباحًا: اليوجا في شرفة FIT
  • 12:15 ظهرًا: بالم شوجار ريبابليك في WET Deck

 

الأحد 27 مارس:

  • 9:00 صباحًا: تمرين Killer Core في سيكرت جاردن
  • 10:00 صباحًا: تمرين Legs & Glutes HIIT Workout  عالي الجهد في شرفة FIT
  • 11:15: تمرين Paddle Board على الشاطئ

 


Johnson & Johnson Announces Landmark Agreement to Enable its COVID-19 Vaccine to be Manufactured and Made Available by an African Company for People Living in Africa




Aspen will manufacture and provide the Johnson & Johnson COVID-19 vaccine under its own brand name per the terms of agreement

Ensuring equitable, global access to COVID-19 vaccines has been a pillar of Johnson & Johnson's response since the earliest days of the pandemic

The production of COVID-19 vaccines on multiple continents is critical to supporting an equitable response, controlling the pandemic, and improving long-term health security

NEW BRUNSWICK, N.J., March 8, 2022 /PRNewswire/Knowledge Bylanes -- Johnson & Johnson (NYSE: JNJ) (the Company) today announced the completion of a landmark agreement between Janssen Pharmaceuticals, Inc., and manufacturer Aspen SA Operations (Pty) Ltd, based in South Africa, to enable the first COVID-19 vaccine to be manufactured and made available by an African company for people living in Africa, with the goal of increasing COVID-19 vaccination rates across the continent.

Expanding global vaccination coverage is critically important to controlling the COVID-19 pandemic and reducing the risk of emergence of new SARS-CoV-2 variants. Currently, only about 12 percent of people in Africa are fully vaccinated, which is well below the World Health Organization's target of 70 percent population coverage for all countries.

Our response to the COVID-19 pandemic has been guided by the conviction that unless everyone is safe, no one is safe, which is why we worked to develop and deliver a vaccine that can protect the health of everyone, everywhere.

"From the outset of this pandemic we aimed to develop a simple-to-use and accessible vaccine that could be transported around the world through standard vaccine distribution channels," said Martin Fitchet, M.D., Head of Global Public Health, Johnson & Johnson, Cilag GmbH International. "We initiated clinical trials in all regions of the world to generate evidence across multiple geographies and diverse, at-risk populations and forged a strategic partnership with Aspen in Africa and others to manufacture our vaccine globally. We're proud to take our long-standing collaboration with Aspen to the next level, to continue to address the COVID-19 threat and lay the groundwork for a healthier, more secure future for people in Africa."

To date, Johnson & Johnson has shipped more than 200 million vaccine doses to Africa through a combination of our advance purchase agreements with the African Vaccine Acquisition Trust, South Africa and Gavi, the Vaccine Alliance, on behalf of the COVAX Facility, along with government donations. As one of our contract manufacturers since November 2020, Aspen has been a significant supplier within the Johnson & Johnson global network.

The agreement enables Aspen, using COVID-19 vaccine drug substance supplied by Johnson & Johnson, to produce Aspen-branded finished vaccine and make doses available to the public sector in Africa, including all 55 Member States of the African Union and key multilateral entities supporting Africa's COVID-19 vaccination drive, inclusive of the African Vaccine Acquisition Trust (AVAT), and the COVAX Facility.

"With the conclusion of this agreement, our vision for Africa's own vaccine has become a reality," said Stephen Saad, Aspen Group Chief Executive. "This has been achieved through tremendous teamwork and collaboration between Johnson & Johnson and Aspen. Through this agreement and their earlier actions, Johnson & Johnson has demonstrated its commitment to our continent. Initially by choosing Aspen, located in Africa, as a core manufacturing partner, and then by showing resolve and dedication to a technical transfer process during the most stringent lockdown periods of the COVID outbreak."

Johnson & Johnson's Equitable Response to COVID-19
A commitment to global equity has guided the Company's response since the beginning of the pandemic, starting with the decision to pursue a vaccine that can provide protection with a single dose and be easily stored and distributed with standard refrigeration globally, including in resource-limited, rural or remote settings.

Johnson & Johnson supported the development of its vaccine with a truly global and inclusive clinical research program that studied the vaccine across the U.S., Europe, Africa, Asia and Latin America as we sought to generate evidence across multiple geographies and diverse, at-risk populations, including in resource-limited settings. We complemented this by supporting a large-scale implementation study for our vaccine in South Africa. The "Sisonke" study made the Johnson & Johnson COVID-19 vaccine available to 500,000 frontline healthcare workers across the country.

In parallel, the Company forged a global supply network that included Aspen and partners in the U.S., Europe and India, and entered into advance purchase agreements with Gavi, on behalf of the COVAX Facility, and AVAT to supply 420 million vaccine doses to low- and middle-income countries (LMICs) through 2022.

"The urgency and necessity of developing and delivering our COVID-19 vaccine required our R&D teams to find new and exciting ways to use our novel vaccine technology to rapidly progress our science and maximize our impact for humanity," said Penny Heaton, M.D., Global Therapeutic Area Head, Vaccines, Janssen Research & Development, LLC. "We have proudly contributed to protecting hundreds of millions of people from COVID-19. Our experiences will have major benefits for the future of vaccine development and Johnson & Johnson's ongoing research and development programs as we continue to bring cutting-edge science to bear on complex health challenges."

In 2021, Johnson & Johnson provided its vaccine globally at a not-for-profit price, and through its advance purchase agreements and country donations, shipped approximately 70% of its global vaccine supply to LMICs. The Company remains committed to ensuring its vaccine is accessible to people around the world and continues to advocate that governments with available doses follow the example of the U.S., European Union and others and immediately ramp up dose sharing, particularly through the COVAX Facility.

Johnson & Johnson has also pledged its support to the COVAX Humanitarian Buffer through an agreement with the U.S. Government and Gavi. This agreement enables access to our COVID-19 vaccine for the world's most vulnerable people, such as those living in conflict zones and other humanitarian settings who are at risk of exclusion from traditional vaccination campaigns.

About the Johnson & Johnson COVID-19 Vaccine
The Johnson & Johnson COVID-19 vaccine has a robust profile in scientific, clinical and real-world studies, generating strong, persistent activity against SARS-CoV-2 and variants such as Delta and Omicron. The vaccine's efficacy, both as a single dose and in boosted regimens, combined with its compatibility with standard refrigeration requirements, uniquely positions it for ease of deployment in any setting.

The Johnson & Johnson COVID-19 vaccine has an Emergency Use Listing (EUL) from the World Health Organization (WHO) and has been authorized in many other countries worldwide, including 50 countries in Africa. The vaccine is authorized by the U.S. Food and Drug Administration (FDA) through an Emergency Use Authorization (EUA), and has a Conditional Marketing Authorization from the European Commission for use across the European Union (EU).

On February 28, the European Medicines Agency approved an extension of the shelf-life of the Johnson & Johnson COVID-19 vaccine to 11 months when refrigerated at temperatures of 2 to 8 degrees Celsius (36 to 46 degrees Fahrenheit). On March 7, Johnson & Johnson confirmed that the U.S. FDA has extended the shelf-life of the Company's vaccine from six months to nine months when stored at these same temperatures. These decisions are based on data from ongoing stability assessment studies. Johnson & Johnson has also submitted these data regarding the vaccine's shelf-life to the WHO, and a decision is expected shortly.

About the Janssen Pharmaceutical Companies of Johnson & Johnson
At Janssen, we're creating a future where disease is a thing of the past. We're the Pharmaceutical Companies of Johnson & Johnson, working tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity and healing hopelessness with heart. We focus on areas of medicine where we can make the biggest difference: Cardiovascular & Metabolism, Immunology, Infectious Diseases & Vaccines, Neuroscience, Oncology and Pulmonary Hypertension.

Learn more at www.janssen.com. Follow us at @JanssenUS and @JanssenGlobal. Janssen Research & Development, LLC, Janssen Pharmaceuticals Inc., and Cilag GmbH International are part of the Janssen Pharmaceutical Companies of Johnson & Johnson.

About Johnson & Johnson
At Johnson & Johnson, we believe good health is the foundation of vibrant lives, thriving communities and forward progress. That's why for more than 130 years, we have aimed to keep people well at every age and every stage of life. Today, as the world's largest and most broadly-based healthcare company, we are committed to using our reach and size for good. We strive to improve access and affordability, create healthier communities, and put a healthy mind, body and environment within reach of everyone, everywhere. We are blending our heart, science and ingenuity to profoundly change the trajectory of health for humanity. Learn more at www.jnj.com. Follow us at @JNJNews.

Cautions Concerning Forward-Looking Statements
This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding an agreement with Aspen SA Operations (Pty) Ltd relating to the development, manufacture and distribution of the Johnson & Johnson COVID-19 vaccine. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Janssen Pharmaceuticals, Inc., the Janssen Pharmaceutical Companies, and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to: the potential that the expected benefits and opportunities of the agreement may not be realized or may take longer to realize than expected; challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; manufacturing difficulties and delays; competition, including technological advances, new products and patents attained by competitors; challenges to patents; product efficacy or safety concerns resulting in product recalls or regulatory action; changes in behavior and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended January 2, 2022, including in the sections captioned "Cautionary Note Regarding Forward-Looking Statements" and "Item 1A. Risk Factors," and in Johnson & Johnson's subsequent Quarterly Report on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. None of Janssen Pharmaceuticals, Inc., the Janssen Pharmaceutical Companies nor Johnson & Johnson undertakes to update any forward-looking statement as a result of new information or future events or developments.
=